From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Cardiology>
  4. Summary and Comment

Statin plus Niacin Benefits CAD Patients with Low HDL

How well does combination lipid-modifying therapy benefit patients with coronary artery disease (CAD) and low HDL-cholesterol levels? In this 3-year, double-blind trial, researchers randomized 160 such patients (HDL, ≤35 mg/dL in men and ≤40 mg/dL in women) to 1 of 4 regimens: simvastatin and niacin; antioxidants (vitamin E, vitamin C, beta-carotene, and selenium); simvastatin and niacin plus antioxidants; or matching placebos. The primary endpoints were 3-year angiographic evidence of change in percent stenosis and 38-month incidence of cardiac-related death, nonfatal MI, stroke, or revascularization for worsening ischemia.

In the antioxidants-alone group, no lipid-modifying benefit was found. In the simvastatin-niacin group, mean LDL level dropped by 42% and mean HDL level increased by 26% from baseline to 3-year follow-up. Adding antioxidants to the simvastatin-niacin regimen actually diminished its HDL-raising effect.

The mean percent stenosis in proximal arteries increased by 3.9% in placebo recipients, by 1.8% in antioxidants-alone recipients, and by 0.7% in recipients of simvastatin-niacin plus antioxidants; in the simvastatin-niacin (without antioxidants) group, a decrease of 0.4% was found. Incidence of the combined clinical endpoint (defined above) was about 90% lower in the simvastatin-niacin group than in the placebo group (3% vs. 24%, P=0.03); the differences between other treatments and placebo were nonsignificant.

Comment: This study documents clinical and angiographic benefits of combination lipid-altering therapy in CAD patients with low HDL -- benefits greater than what would be expected from statins alone. An editorialist emphasizes that antioxidants attenuated the benefits of statin-niacin treatment. These findings represent a substantial advance in knowledge with direct clinical relevance for the many CAD patients with low HDL-cholesterol levels.

— JoAnne M. Foody, MD

Published in Journal Watch Cardiology January 18, 2002

Citation(s):

Brown BG et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 Nov 29; 345:1583-92.

Freedman JE. Antioxidant versus lipid-altering therapy -- Some answers, more questions. N Engl J Med 2001 Nov 29; 345:1636-7.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2002. Massachusetts Medical Society. All rights reserved.